This previously little-known immunotherapy stock recently saw its shares soar nearly 249% — and its market value surge from $300 million to more than $1 billion — in a single day. Why? The company could hold the solution to one of the biggest potential problems when it comes to the future of the coronavirus pandemic: the emergence of new strains of the virus that vaccines are not effective against. How is this company tackling this problem – and could its product make it the next Moderna? CLICK HERE.